Bluebird Bio Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bluebird Bio Inc 's ROA in the first quarter of 2025?
Bluebird Bio Inc achieved a return on average assets (ROA) of 45.55 % in its first quarter of 2025, this is above BLUE's average return on assets of -19.71%.
Bluebird Bio Inc assets over the 12 months ending in its first quarter of 2025 are valued at $306 million

Despite the company's net income deteriorating, Bluebird Bio Inc was able to improve its ROA compared to the fourth quarter of 2024.

However, within the Healthcare sector 31 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2025 quarter, so far to 134, from total ROA ranking in the fourth quarter of 2024 at 3000.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Total Assets Change	-32.41 %	-31.9 %	-11.29 %	-1.49 %	3.26 %
Y / Y Net Income Change	-	12.93 %	-	-	-
Net Income (TTM) in million	139	0	-16	-103	-166
Return On Assets (TTM)	45.55 %	-0.02 %	-4.28 %	-26.9 %	-43.09 %
BLUE's Total Ranking	# 134	# 3000	# 2971	# 3649	# 3913
Total Assets (TTM) in million	296	286	285	358	438
Seq. Total Assets Change	3.53 %	0.36 %	-20.42 %	-18.25 %	4.31 %
Seq. Net Income Change	-	240418.97 %	-	-	-

BLUE's 5 Years Annual ROA >> Back to BLUE Management Effectiveness >> Compare BLUE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 6
Sector	# 32
Overall	# 127

Return On Assets Statistics
High	Average	Low
93.86 %	-19.71 %	-83.33 %
(Dec 31 2013)		(Sep 30 2022)

Financial Statements
Bluebird Bio Inc 's Assets	$ 296 million	BLUE's Balance sheet
Bluebird Bio Inc 's Income	$ 0 million	Quarterly BLUE's Income Statement
BLUE's Income by Division		See BLUE's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-31.9 %	52.21 %	-45.28 %	-68.49 %	-7.41 %
Total Assets in million	286	420	276	504	1,599
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	0	0	-267	-819	-619
Annual Return On Assets	-0.02 %	0.03 %	-96.66 %	-162.58 %	-38.68 %

BLUE's 5 Years Annual ROA >> Back to BLUE Management Effectiveness >> Compare BLUE ROA to its Competitors

More Return On Assets Ratios
BLUE's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BLUE's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BLUE's Competitors
Subscribers only: Roa for Bluebird Bio Inc 's Suppliers
Subscribers only: Return On Assets for BLUE's Customers

You may also want to know
BLUE's Roi	BLUE's Inventory Turnover Ratio	BLUE's Growth Rates	BLUE's Dividend Comparisons
	BLUE's Profitability Ratios	BLUE's Asset Turnover Ratio	BLUE's Dividend Growth
BLUE's Roe	BLUE's Valuation Ratios	BLUE's Financial Strength Ratios	BLUE's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector	ROA
Nkgen Biotech Inc	108.74 %
Camp4 Therapeutics Corporation	99.51 %
Semnur Pharmaceuticals Inc	97.62 %
Alumis inc	92.46 %
Oak Woods Acquisition Corp	87.29 %
Tao Synergies Inc	70.91 %
Outlook Therapeutics Inc	68.23 %
Earth Science Tech Inc	62.66 %
Avalo Therapeutics Inc	58.88 %
Interpace Biosciences Inc	56.00 %
Exelixis Inc	51.45 %
Stablecoin Development Corporation	50.36 %
Synlogic Inc	47.83 %
Adma Biologics Inc	46.83 %
Agios Pharmaceuticals Inc	46.06 %
Pharmacyte Biotech Inc	44.19 %
Gridai Technologies Corp	43.94 %
Medinotec Inc	40.68 %
Sbc Medical Group Holdings Incorporated	40.28 %
Dariohealth Corp	38.41 %
Seres Therapeutics Inc	36.27 %
Longduoduo Co Ltd	34.93 %
Edwards Lifesciences Corporation	33.98 %
Cytomx Therapeutics Inc	32.17 %
Bluebird Bio Inc	31.57 %
Novavax inc	29.99 %
Ptc Therapeutics inc	29.31 %
Nutriband Inc	27.24 %
Idexx Laboratories Inc	26.97 %
Mettler toledo International Inc	26.04 %

Date modified: 2026-09-26T07:02:51+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.